MacroGenics, Inc. - stock earnings
MGNX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -45.8 million USD | 11.0 million USD |
| 2023Q3 | 17.6 million USD | 10.4 million USD |
| 2023Q2 | 57.5 million USD | 13.1 million USD |
| 2023Q1 | -38.2 million USD | 24.2 million USD |
| 2022Q4 | 12.8 million USD | 71.2 million USD |
| 2022Q3 | -24.7 million USD | 41.7 million USD |
| 2022Q2 | -40.8 million USD | 26.0 million USD |
| 2022Q1 | -66.2 million USD | 10.7 million USD |
| 2021Q4 | -58.0 million USD | 13.6 million USD |
| 2021Q3 | -52.9 million USD | 15.6 million USD |
| 2021Q2 | -39.9 million USD | 30.4 million USD |
| 2021Q1 | -51.3 million USD | 16.1 million USD |
| 2020Q4 | -2.1 million USD | 51.7 million USD |
| 2020Q3 | -36.0 million USD | 17.4 million USD |
| 2020Q2 | -46.9 million USD | 15.6 million USD |
| 2020Q1 | -44.7 million USD | 13.0 million USD |
| 2019Q4 | -30.4 million USD | 24.6 million USD |
| 2019Q3 | -44.6 million USD | 18.0 million USD |
| 2019Q2 | -31.8 million USD | 10.0 million USD |
| 2019Q1 | -45.0 million USD | 9.5 million USD |
| 2018Q4 | -44.6 million USD | 16.5 million USD |
| 2018Q3 | -34.0 million USD | 20.6 million USD |
| 2018Q2 | -43.2 million USD | 18.6 million USD |
| 2018Q1 | -49.5 million USD | 4.5 million USD |
| 2017Q4 | 105.7 million USD | 154.3 million USD |
| 2017Q3 | -47.0 million USD | 1.1 million USD |
| 2017Q2 | -40.7 million USD | 1.1 million USD |
| 2017Q1 | -37.7 million USD | 1.3 million USD |
| 2016Q4 | -34.8 million USD | 9.5 million USD |
| 2016Q3 | -33.8 million USD | 2.0 million USD |
| 2016Q2 | 40.5 million USD | 78.5 million USD |
| 2016Q1 | -30.4 million USD | 1.9 million USD |
| 2015Q4 | -28.5 million USD | 9.4 million USD |
| 2015Q3 | -15.4 million USD | 14.7 million USD |
| 2015Q2 | -21.4 million USD | 5.6 million USD |
| 2015Q1 | 45.1 million USD | 71.2 million USD |
| 2014Q4 | -19.0 million USD | 5.4 million USD |
| 2014Q3 | -3.9 million USD | 18.3 million USD |
| 2014Q2 | -12.3 million USD | 9.2 million USD |
| 2014Q1 | -3.1 million USD | 14.4 million USD |
| 2013Q4 | -3.2 million USD | 14.7 million USD |
| 2013Q3 | 6.6 million USD | 20.1 million USD |
| 2013Q2 | -294000 USD | 11.8 million USD |
| 2013Q1 | -3.4 million USD | 10.1 million USD |
| 2012Q4 | -2.1 million USD | 9.4 million USD |
| 2012Q3 | 2.6 million USD | 15.5 million USD |
| 2012Q2 | 7.9 million USD | 37.9 million USD |
| 2011Q4 | 6.7 million USD | 57.2 million USD |
MGNX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -9.1 million USD | 58.7 million USD |
| 2022 | -120.0 million USD | 151.9 million USD |
| 2021 | -190.9 million USD | 75.6 million USD |
| 2020 | -117.8 million USD | 97.8 million USD |
| 2019 | -151.8 million USD | 62.0 million USD |
| 2018 | -171.5 million USD | 60.1 million USD |
| 2017 | -19.6 million USD | 155.5 million USD |
| 2016 | -58.5 million USD | 86.6 million USD |
| 2015 | -20.1 million USD | 100.9 million USD |
| 2014 | -38.3 million USD | 47.3 million USD |
| 2013 | -260835 USD | 56.8 million USD |
| 2012 | 8.4 million USD | 59.6 million USD |
| 2011 | 6.7 million USD | 47.1 million USD |
MGNX
Price: $14.56
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.15 USD
P/E Ratio: 21.30
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 382181
Ebitda: -45.8 millionMarket Capitalization: 1.1 billion